Supply constraints removed, stronger 2H ahead

AMS

Add

AMS' 1H22 result saw a beat on EBITDA (A$3.2m vs A$2.5m MorgansE) although further upside was...

Back to Latest Research

Full Article

  • Print this page
  • Copy Link